H.C. Wainwright Sticks to Their Buy Rating for AC Immune SA (ACIU)

H.C. Wainwright analyst Andrew Fein reiterated a Buy rating on AC Immune SA (ACIUResearch Report) on June 17 and set a price target of $16.00. The company’s shares closed last Friday at $2.60, close to its 52-week low of $2.06.

According to TipRanks.com, Fein ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -24.0% and a 26.1% success rate. Fein covers the Healthcare sector, focusing on stocks such as DBV Technologies SA – American, Amylyx Pharmaceuticals Inc, and Global Blood Therapeutics.

AC Immune SA has an analyst consensus of Moderate Buy, with a price target consensus of $15.50.

See Insiders’ Hot Stocks on TipRanks >>

AC Immune SA’s market cap is currently $217.2M and has a P/E ratio of -2.47.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

AC Immune SA is a clinical stage biopharmaceutical company, which engages in developing therapeutic and diagnostic products. It leverages proprietary technology platforms to discover, design, and develop novel, proprietary medicines for prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The company was founded by Jean-Marie Lehn, Claude Nicolau, Roscoe Brady, Fred van Leuven, Ruth Greferath, Andrea Pfeifer, and Alexey V. Eleesiv on February 13, 2003 and is headquartered in Lausanne, Switzerland.

Read More on ACIU:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More

Latest News Feed